Evidence suggests that altered metabolism can have an important role in the development of HIV‑associated wasting
Dosage and Administration
Your patients can self-administer Serostim®1
Serostim® dosage and administration for the treatment of
Serostim® is administered by subcutaneous injection (SC). The usual starting dose of Serostim® is 0.1 mg/kg once daily (up to a total dose of 6 mg). Serostim® should be administered subcutaneously once daily at bedtime according to the following body weight-based dosage recommendations:
|> 55 kg (> 121 lb)||6 mg* SC daily|
|45-55 kg (99-121 lb)||5 mg* SC daily|
|35-45 kg (75-99 lb)||4 mg* SC daily|
|< 35 kg (< 75 lb)||0.1 mg/kg SC daily|
*Based on an approximate daily dosage of 0.1 mg/kg.
Serostim® treatment should always be carried out under the regular guidance of a healthcare provider who is experienced in the diagnosis and management of HIV.
Serostim® dosage forms and strengths
Serostim® is available as 5 mg and 6 mg single-dose vials and a 4 mg multidose vial.
Treatment with Serostim® 0.1 mg/kg every other day was associated with fewer side effects, and resulted in a similar improvement in work output, as compared with Serostim® 0.1 mg/kg daily. Therefore, a starting dose of Serostim® 0.1 mg/kg every other day should be considered in patients at increased risk for adverse effects related to Serostim® treatment (i.e., glucose intolerance).
Patients should be thoroughly instructed in the importance of proper disposal of needles and syringes and cautioned against any reuse. Counsel patients that they should never share Serostim® with another person, even if the needle is changed.
In general, dose reductions (i.e., reducing the total daily dose or the number of doses per week) should be considered for individuals with side effects potentially related to Serostim® treatment.
Injection sites, which may be located on the thigh, upper arm, abdomen, or buttock, should be rotated to avoid local irritation.
Monitoring Serostim® treatment progress
Follow-up visits allow your patients to set goals and track their progress during treatment. Consider the following methods for assessing symptoms and monitoring your patients while they’re taking Serostim®:
- Measuring body weight and reviewing weight history, including premorbid or prediagnosis weight as well as changes in weight over time
- Calculating body mass index (BMI)
- Evaluating muscle tone and physical endurance
- Assessing patient-reported outcomes
- Visually examining physical appearance
- BIS and DXA
- Asking your patients about their treatment experience, including wasting symptoms, changes in appearance, energy levels, and whether any changes in weight are affecting their health and how they are feeling